Autism Spectrum DisorderNCT05830591
Gut-oral Axis Microbiome in Autism Spectrum Disorders
An observational study of Autism Spectrum Disorder and Microbiota, run by IRCCS Burlo Garofolo at 1 site in Italy.
Trial summary
Autism Spectrum Disorder (ASD) is a neurodevelopment disorder characterized by impairment in social interaction, communication, and behavior, as well as sensory challenges. In addition, secondary symptoms can appear, such as gastrointestinal disorders. Read more about this study
- Who is it for?
- Ages 1 year to 17 years
- Conditions the study is for
- Autism Spectrum Disorder, Microbiota
- What is being tested?
- Characterization of the microbiome in oral and fecal samples
- Type of treatment
- Pill or oral medicine
- How many people
- 86 participants
- Where
- 1 siteItaly
- Study dates
- 20 May 2021to 31 Dec 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 17 years
- All sexes
- No healthy volunteers
- Child
Study population: Pediatric subjects: * children coming to the Division of Child Neurology and Psychiatry for the first clinical evaluation (1 year to 5 years old) * children with confirmed ASD diagnosis (6 years to 17 years old) coming to the Odonto-Stomatology Department for the periodical dental hygiene session. * children control group with matched demographic characteristics accessing our Institute for different purposes
Who may be able to join
- Case group
- Caucasian
- Diagnosed with ASD or with a newly formulated diagnosis of ASD
- Aged between 1 and 17 years
- Control group
- Caucasian
Show all 9Show fewer
- Healthy at the time of sampling
- No ASD or other neurological disorders
- Aged between 1 and 17 years
Who cannot join
- Antibiotic use in the month before sample collection
- Probiotic use in the month before sample collection
- Other neurological diseases
- Chronic inflammatory diseases
- The use of constipation drugs during the three days before sample collection
Trial locations and contacts
1 site in 1 country.
Italy1 site, 1 recruiting
- Recruiting
Institute for Maternal and Child Health - IRCCS "Burlo Garofolo"
Trieste, 34137
Manola Comar, BSc, +39040.3785527, manola.comar@burlo.trieste.it
Manola Comar, BSc, +39.040.3785.527, manola.comar@burlo.trieste.it
About this study
Official title: The Role of Gut-oral Axis Microbiome in Autism Spectrum Disorders
Autism Spectrum Disorder (ASD) is a neurodevelopment disorder characterized by impairment in social interaction, communication, and behavior, as well as sensory challenges. In addition, secondary symptoms can appear, such as gastrointestinal disorders. Gut microbiota has an important role in the harvest of nutrients and energy from our diet. It influences a wide range of metabolic, developmental, and physiological processes such as the maintenance of the gut epithelial layer, immune system development, protection against pathogens, detoxification and xenobiotics degradation. The ecosystem of a healthy human gastrointestinal (GI) tract is mainly populated by Firmicutes and Bacteroidetes phyla, to a lesser extent by Actinobacteria and Proteobacteria, in this case the microbiota is in an eubiosis condition. Whether a disturbance of the microbial ecosystem occurs, gut microbiota is in a dysbiosis condition and it could lead different metabolic disorders. The two-way communication between gut microbiota and central nervous system (CNS) affects stress response, pain perception, neurochemistry and several disorders. The gut microbiota in ASD patients revealed some peculiarities such as the high percentage of Propionibacter and Clostridium, well known for their production of pro inflammatory metabolites, or an increment of Sutterella spp. and Ruminococcus torques, which are negatively associated with the health of the gut. Recent studies suggest that also the oral microbiota may be involved in ASD symptoms assuming the existence of a "microbiota-oral-brain axis". ASD patients are often suffering of several oral cavity disorders like caries, gingivitis and periodontitis, probably due to the poor oral hygiene. These disorders are linked to a dysbiosis of the oral microbiota: the characterization of the ASD subjects oral microbiota showed a lower biodiversity of bacteria species and different levels of specific bacteria, comparing to the controls. Several studies suggest that some bacteria species invade the blood-brain barriers as well as their metabolites, triggering inflammatory response and an alteration of the metabolic activity in the CNS. It has been demonstrated that ASD patients have a high level of pro-inflammatory cytokines and chemokines in the cerebrospinal fluid and an upregulation of the microglia. The oral microbiota could also affect the lower GI tract and have a significant role within the ASD-associated GI disorders and CNS inflammation
Read the detailed description
Autism Spectrum Disorder (ASD) is a neurodevelopment disorder characterized by impairment in social interaction, communication, and behavior, as well as sensory challenges. In addition to the main symptoms, secondary symptoms can appear, such as gastrointestinal disorders. Gut microbiota has an important role in the harvest of nutrients and energy from our diet. Furthermore, it influences a wide range of metabolic, developmental, and physiological processes such as the maintenance of the gut epithelial layer, immune system development, protection against pathogens, detoxification and xenobiotics degradation. The ecosystem of a healthy human gastrointestinal (GI) tract is mainly populated by Firmicutes and Bacteroidetes phyla, to a lesser extent by Actinobacteria and Proteobacteria, in this case the microbiota is in an eubiosis condition. Whether a disturbance of the microbial ecosystem occurs, gut microbiota is in a dysbiosis condition and it could lead different metabolic disorders. For instance, the two-way communication between gut microbiota and central nervous system (CNS) affects stress response, pain perception, neurochemistry and several disorders. The gut microbiota in ASD patients revealed some peculiarities such as the high percentage of Propionibacter and Clostridium, well known for their production of pro inflammatory metabolites (like some short-chain fatty acids: acetate and propionate) or an increment of Sutterella spp. and Ruminococcus torques in feces of ASD children, which are negatively associated with the health of the gut. Similarly, very recent studies suggest that also the oral microbiota may be involved in ASD symptoms assuming the existence of a "microbiota-oral-brain axis". ASD patients are often suffering of several oral cavity disorders like caries, gingivitis and periodontitis, probably due to the poor oral hygiene. These disorders are linked to a dysbiosis of the oral microbiota: as a matter of fact, the characterization of the ASD subjects oral microbiota showed a lower biodiversity of bacteria species and different levels of specific bacteria, comparing to the controls. Several studies suggest that some bacteria species invade the blood-brain barriers as well as their metabolites, triggering inflammatory response and an alteration of the metabolic activity in the CNS. Interestingly, it has been demonstrated that ASD patients have a high level of pro-inflammatory cytokines and chemokines in the cerebrospinal fluid and an upregulation of the microglia. The oral microbiota could also affect the lower gastro-intestinal (GI) tract, given the transit of bacteria from the oral cavity to the gut, leading to different effects depending on the type of bacteria. This implies that an oral microbiota dysbiosis may be one of the leading causes of the gut microbiota dysbiosis reported in numerous ASD studies as demonstrated by studies of the Human Microbiome Project, the 45% of the gut and oral microbiota bacteria over-lap. In light of these facts, the oral microbiota could have a significant role within the ASD-associated GI disorders and CNS inflammation. The main objective of this project is to identify descriptive features relative to bacterial species in gut and oral microbiota of pediatric subjects with ASD diagnosis. The purpose is to find whether these species overlap in order to identify descriptive features of ASD, which are collectable by means of a simple oral swab (rather than a fecal sample). These species will be identified with both DNA sequencing, followed by bioinformatic analysis, and a culturomic approach. The innovative approach of "network analysis" will be employed in order to find definite bacterial consortia, named Species Interacting Groups (SIGs) able to collect the abovementioned featuring species. These data could be useful for a better ASD description in terms of bacterial compositional differences, especially within a defined pediatric group.
- Conditions
- Autism Spectrum Disorder, Microbiota
- Being tested
- Characterization of the microbiome in oral and fecal samples
- Keywords
- Autism Spectrum Disorder, Microbiota, Inflammatory cytokines
- Medical subject headings
- Autism Spectrum Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Characterization of the microbiome in oral and fecal samplesOther
The oral and fecal samples are collected during the periodical dental hygiene session at the odonto-stomatology unit and during day hospital for younger children admitted for the first clinical evaluation at Division of Child Neurology and Psychiatry. Procedures will follow standardized protocols.
| Study group | Role | What they receive |
|---|---|---|
| Children with autism disorders 1-5 years | Children coming to the Division of Child Neurology and Psychiatry for the first clinical evaluation (1 year to 5 years old) Receives: Other: Characterization of the microbiome in oral and fecal samples | |
| Children with autism disorders 6-17 years | Children with confirmed ASD diagnosis (6 years to 17 years old) coming to the Odonto-Stomatology Department for the periodical dental hygiene session Receives: Other: Characterization of the microbiome in oral and fecal samples | |
| Children control group | Children with matched demographic characteristics accessing our Institute for different purposes Receives: Other: Characterization of the microbiome in oral and fecal samples |
What is being measured
The primary outcome is the main question the study is designed to answer.
To compare oral and GI microbiota
Oral and GI bacterial species will be evaluated in oral and fecal samples collected and compared through bioinformatic and statistical analysis among case and control groups to isolate the discriminant ones. The technical activity is focused on samples DNA extraction and sequencing and on a culturomic approach.
Measured: At baseline
Secondary outcomes (4)
To evaluate the association between the key bacteria species found in ASD microbiota and soluble concentration of salivary cytokines
Oral and GI bacterial species will be evaluated in oral and fecal samples. The soluble concentrations (picograms per millilitre) of a panel of 27 cytokines and chemokines will be simultaneously assessed in saliva samples.
Measured: At baseline
To evaluate the association between the key bacteria species found in ASD microbiota and soluble concentration of salivary chemokines
Oral and GI bacterial species will be evaluated in oral and fecal samples. The soluble concentrations (picograms per millilitre) of a panel of 27 cytokines and chemokines will be simultaneously assessed in saliva samples.
Measured: At baseline
To evaluate the association between the microbiota structure and the severity of the ASD symptoms
Oral and GI bacterial species will be evaluated in oral and fecal samples. Clinical data will be collected from medical records.
Measured: At baseline
To evaluate the association between the microbiota structure and eating habits of ASD children
A food diary will be distributed at enrollment to evaluate eating habits of ASD children
Measured: At baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Apr 2023
- Study start20 May 2021
- Primary completion31 Dec 2024 (estimated)
- Study completion31 Dec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Autism Spectrum DisorderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 86 participants (estimated)
Sponsor and investigators
- Lead sponsor
- IRCCS Burlo Garofolo
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Manola Comar, BSc, Study director, Institute for Maternal and Child Health IRCCS Burlo Garofolo
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05830591
- Sponsor's protocol ID
- RC 20/21
- Status last verified
- Jun 2024
- First submitted
- 29 Mar 2023
- Last updated
- 14 Jun 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 14 Jun 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of Gut-oral Axis Microbiome in Autism Spectrum Disorders
- ClinicalTrials.gov ID
- NCT05830591
- Acronym / sponsor ID
- RC 20/21
- Conditions
- Autism Spectrum Disorder, Microbiota
- Keywords
- Autism Spectrum Disorder, Microbiota, Inflammatory cytokines
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 86 participants (estimated)
- Lead sponsor
- IRCCS Burlo GarofoloUniversity, hospital or other
- Study start
- 20 May 2021 (actual)
- Primary completion
- 31 Dec 2024 (estimated)
- Study completion
- 31 Dec 2024 (estimated)
- First posted
- 26 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Autism Spectrum Disorder (ASD) is a neurodevelopment disorder characterized by impairment in social interaction, communication, and behavior, as well as sensory challenges. In addition, secondary symptoms can appear, such as gastrointestinal disorders. Gut microbiota has an important role in the harvest of nutrients and energy from our diet. It influences a wide range of metabolic, developmental, and physiological processes such as the maintenance of the gut epithelial layer, immune system development, protection against pathogens, detoxification and xenobiotics degradation. The ecosystem of a healthy human gastrointestinal (GI) tract is mainly populated by Firmicutes and Bacteroidetes phyla, to a lesser extent by Actinobacteria and Proteobacteria, in this case the microbiota is in an eubiosis condition. Whether a disturbance of the microbial ecosystem occurs, gut microbiota is in a dysbiosis condition and it could lead different metabolic disorders. The two-way communication between gut microbiota and central nervous system (CNS) affects stress response, pain perception, neurochemistry and several disorders. The gut microbiota in ASD patients revealed some peculiarities such as the high percentage of Propionibacter and Clostridium, well known for their production of pro inflammatory metabolites, or an increment of Sutterella spp. and Ruminococcus torques, which are negatively associated with the health of the gut. Recent studies suggest that also the oral microbiota may be involved in ASD symptoms assuming the existence of a "microbiota-oral-brain axis". ASD patients are often suffering of several oral cavity disorders like caries, gingivitis and periodontitis, probably due to the poor oral hygiene. These disorders are linked to a dysbiosis of the oral microbiota: the characterization of the ASD subjects oral microbiota showed a lower biodiversity of bacteria species and different levels of specific bacteria, comparing to the controls. Several studies suggest that some bacteria species invade the blood-brain barriers as well as their metabolites, triggering inflammatory response and an alteration of the metabolic activity in the CNS. It has been demonstrated that ASD patients have a high level of pro-inflammatory cytokines and chemokines in the cerebrospinal fluid and an upregulation of the microglia. The oral microbiota could also affect the lower GI tract and have a significant role within the ASD-associated GI disorders and CNS inflammation
Detailed description
Autism Spectrum Disorder (ASD) is a neurodevelopment disorder characterized by impairment in social interaction, communication, and behavior, as well as sensory challenges. In addition to the main symptoms, secondary symptoms can appear, such as gastrointestinal disorders. Gut microbiota has an important role in the harvest of nutrients and energy from our diet. Furthermore, it influences a wide range of metabolic, developmental, and physiological processes such as the maintenance of the gut epithelial layer, immune system development, protection against pathogens, detoxification and xenobiotics degradation. The ecosystem of a healthy human gastrointestinal (GI) tract is mainly populated by Firmicutes and Bacteroidetes phyla, to a lesser extent by Actinobacteria and Proteobacteria, in this case the microbiota is in an eubiosis condition. Whether a disturbance of the microbial ecosystem occurs, gut microbiota is in a dysbiosis condition and it could lead different metabolic disorders. For instance, the two-way communication between gut microbiota and central nervous system (CNS) affects stress response, pain perception, neurochemistry and several disorders. The gut microbiota in ASD patients revealed some peculiarities such as the high percentage of Propionibacter and Clostridium, well known for their production of pro inflammatory metabolites (like some short-chain fatty acids: acetate and propionate) or an increment of Sutterella spp. and Ruminococcus torques in feces of ASD children, which are negatively associated with the health of the gut. Similarly, very recent studies suggest that also the oral microbiota may be involved in ASD symptoms assuming the existence of a "microbiota-oral-brain axis". ASD patients are often suffering of several oral cavity disorders like caries, gingivitis and periodontitis, probably due to the poor oral hygiene. These disorders are linked to a dysbiosis of the oral microbiota: as a matter of fact, the characterization of the ASD subjects oral microbiota showed a lower biodiversity of bacteria species and different levels of specific bacteria, comparing to the controls. Several studies suggest that some bacteria species invade the blood-brain barriers as well as their metabolites, triggering inflammatory response and an alteration of the metabolic activity in the CNS. Interestingly, it has been demonstrated that ASD patients have a high level of pro-inflammatory cytokines and chemokines in the cerebrospinal fluid and an upregulation of the microglia. The oral microbiota could also affect the lower gastro-intestinal (GI) tract, given the transit of bacteria from the oral cavity to the gut, leading to different effects depending on the type of bacteria. This implies that an oral microbiota dysbiosis may be one of the leading causes of the gut microbiota dysbiosis reported in numerous ASD studies as demonstrated by studies of the Human Microbiome Project, the 45% of the gut and oral microbiota bacteria over-lap. In light of these facts, the oral microbiota could have a significant role within the ASD-associated GI disorders and CNS inflammation. The main objective of this project is to identify descriptive features relative to bacterial species in gut and oral microbiota of pediatric subjects with ASD diagnosis. The purpose is to find whether these species overlap in order to identify descriptive features of ASD, which are collectable by means of a simple oral swab (rather than a fecal sample). These species will be identified with both DNA sequencing, followed by bioinformatic analysis, and a culturomic approach. The innovative approach of "network analysis" will be employed in order to find definite bacterial consortia, named Species Interacting Groups (SIGs) able to collect the abovementioned featuring species. These data could be useful for a better ASD description in terms of bacterial compositional differences, especially within a defined pediatric group.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Children with autism disorders 1-5 years | – | Other: Characterization of the microbiome in oral and fecal samplesChildren coming to the Division of Child Neurology and Psychiatry for the first clinical evaluation (1 year to 5 years old) |
| Children with autism disorders 6-17 years | – | Other: Characterization of the microbiome in oral and fecal samplesChildren with confirmed ASD diagnosis (6 years to 17 years old) coming to the Odonto-Stomatology Department for the periodical dental hygiene session |
| Children control group | – | Other: Characterization of the microbiome in oral and fecal samplesChildren with matched demographic characteristics accessing our Institute for different purposes |
Who may qualify
- Ages
- 1 year to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Pediatric subjects: * children coming to the Division of Child Neurology and Psychiatry for the first clinical evaluation (1 year to 5 years old) * children with confirmed ASD diagnosis (6 years to 17 years old) coming to the Odonto-Stomatology Department for the periodical dental hygiene session. * children control group with matched demographic characteristics accessing our Institute for different purposes
Key inclusion criteria (9 listed)
- Case group
- Caucasian
- Diagnosed with ASD or with a newly formulated diagnosis of ASD
- Aged between 1 and 17 years
- Control group
Key exclusion criteria (5 listed)
- Antibiotic use in the month before sample collection
- Probiotic use in the month before sample collection
- Other neurological diseases
- Chronic inflammatory diseases
- The use of constipation drugs during the three days before sample collection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Characterization of the microbiome in oral and fecal samplesThe oral and fecal samples are collected during the periodical dental hygiene session at the odonto-stomatology unit and during day hospital for younger children admitted for the first clinical evaluation at Division of Child Neurology and Psychiatry. Procedures will follow standardized protocols. | Other | Children control group, Children with autism disorders 1-5 years, Children with autism disorders 6-17 years |
Primary outcome
To compare oral and GI microbiota
Time frame: At baseline
Oral and GI bacterial species will be evaluated in oral and fecal samples collected and compared through bioinformatic and statistical analysis among case and control groups to isolate the discriminant ones. The technical activity is focused on samples DNA extraction and sequencing and on a culturomic approach.
4 secondary outcomes
To evaluate the association between the key bacteria species found in ASD microbiota and soluble concentration of salivary cytokines
Time frame: At baseline
To evaluate the association between the key bacteria species found in ASD microbiota and soluble concentration of salivary chemokines
Time frame: At baseline
To evaluate the association between the microbiota structure and the severity of the ASD symptoms
Time frame: At baseline
To evaluate the association between the microbiota structure and eating habits of ASD children
Time frame: At baseline
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jun 2024.
- Individual participant dataSharing planned: Undecided
Related trials for Autism Spectrum Disorder
Not yet recruiting
"Family Resilience And Mind-body Enhancement" (FRAME): A Randomised Controlled Trial
Autism
Recruiting
Trial of Center-Based vs. In-Home Pivotal Response Treatment (PRT) in Autism
Autism, Autism Spectrum Disorder
Recruiting
Neuroimaging Predictors of Improvement to Pivotal Response Treatment (PRT) in Young Children With Autism
Autism Spectrum Disorder, Autism
RecruitingPhase 2
A Study of Esomeprazole in Children With Autism
Autism, Autism Spectrum Disorder
Recruiting
Transcranial Magnetic Stimulation for Restricted and Repetitive Behavior in ASD
Autism Spectrum Disorder, Autism
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Manola Comar, BSc study director
Institute for Maternal and Child Health IRCCS Burlo Garofolo
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Autism Spectrum Disorder and Microbiota, run by IRCCS Burlo Garofolo at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Manola Comar, BSc (+39.040.3785.527, manola.comar@burlo.trieste.it), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To compare oral and GI microbiota (time frame: At baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jun 2024.